Cambrian BioPharma has unveiled its latest pipeline company, Isterian Biotech.   The preclinical start-up is working towards the development of first-in-class small molecule inhibitors of transglutaminase 2 (TG2), one of the major crosslinking enzymes in the human body, which becomes more active during ageing, resulting in fibrotic diseases.  With age a chronic increase of crosslinked proteins […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!